Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 16/20 | 0.39 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.33 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.33 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.33 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.33 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.33 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.33 |
| ▸ | CTRC | Q99895 | 1/20 | 0.32 |
| ▸ | XIAP | P98170 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1324460 | 1.00 | ELANE (0.39) | ELANEGRIN1GRIN2BADORA2AADORA2B | |
| SCHEMBL12122043 | 1.00 | ELANE (0.39) | ELANEGRIN1GRIN2BADORA2AADORA2B | |
| SCHEMBL12122072 | 0.94 | GRIN1 (0.37) | ELANEGRIN1GRIN2BXIAP | |
| SCHEMBL1323845 | 0.94 | GRIN1 (0.37) | ELANEGRIN1GRIN2BXIAP | |
| SCHEMBL1323841 | 0.94 | GRIN1 (0.37) | ELANEGRIN1GRIN2BXIAP | |
| SCHEMBL1323936 | 0.92 | GRIN1 (0.37) | ELANEGRIN1GRIN2BCTRC | |
| SCHEMBL1323939 | 0.92 | GRIN1 (0.37) | ELANEGRIN1GRIN2BCTRC | |
| SCHEMBL12122044 | 0.92 | GRIN1 (0.37) | ELANEGRIN1GRIN2BCTRC | |
| SCHEMBL381046 | 0.92 | ELANE (0.40) | ELANEXIAP | |
| SCHEMBL381915 | 0.92 | ELANE (0.40) | ELANEXIAP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8058272-B2 | Organic compounds | NOVARTIS AG (CH) | 2011-11-15 | — | — | US | claimed |
| US-20100048571-A1 | Organic Compounds | NOVARTIS AG | 2010-02-25 | — | — | US | claimed |
| CN-101595093-A | Organic compound | NOVARTIS AG (CH) | 2009-12-02 | — | — | CN | claimed |
| EP-2086938-A1 | ORGANIC COMPOUNDS | Novartis AG (CH) | 2009-08-12 | — | — | EP | claimed |
| WO-2008073306-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2008-06-19 | — | — | WO | claimed |
| US-8058272-B2 | Organic compounds | NOVARTIS AG (CH) | 2011-11-15 | — | — | US | disclosed |
| US-20100048571-A1 | Organic Compounds | NOVARTIS AG | 2010-02-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100048571-A1 | Organic Compounds | XIAP, BAX, MCL1 | ELANE 2481/4885GRIN1 2799/4885GRIN2B 3107/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.